[Therapy of primary resistant or recurrent @entity4153 with XXXX and @entity1260 ].

@entity1 @entity1665 @entity137 @entity390 @entity4153 @entity7324 @entity5 @entity305 @entity1260
A combination of @entity7324 (3 mg/m2, day 1) and @entity1260 (60 mg/kg, days 1-5 + Mesna) was administered every three weeks to 11 @entity1 with primary resistant and 23 with recurrent @entity4153 . All @entity1 had been pre-treated with chemotherapy, 16 in addition with radiotherapy. At the onset of the @entity7324 - @entity1260 treatment the @entity5 was in a localized regional stage in ten @entity1 , while in 24 it was in a more widely spread stage. In 29 @entity1 whose treatment results could be evaluated the remission rate was 38%, with two complete and nine partial remissions. In a further eight @entity1 the @entity5 was arrested. The @entity1 with complete remission (for 46 and 53 weeks, respectively), those with partial remission (median of 39 weeks) and those with stationary disease (median of 31 weeks) survived significantly longer than those with progressing disease (13 weeks). There was no correlation between treatment result and pre-treatment. On recurrence after complete remission or in the localized regional stage the remission rate was 70% and 60%, respectively, and the survival time was extended in 90% of cases. In addition to @entity390 , @entity1665 and myelosuppression, side-effects included vomiting, reversible CNS symptoms, @entity305 and urotoxicity. On the basis of acceptable @entity137 , combined @entity7324 and @entity1260 constitute an effective treatment of otherwise treatment-refractory cases of @entity4153 .
